Innate Pharma reports 2026 AGM voting results

Innate Pharma S.A. reported the results of its 2026 Annual General Meeting held in Marseille on May 21, 2026.

Accepted by SEC EDGAR 05/22/2026 - 06:01 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Innate Pharma S.A. reported the results of its 2026 Annual General Meeting held in Marseille on May 21, 2026. All resolutions were voted, with a total of 94 votes cast out of 34,872,293 shares representing 34,921,313 voting rights, corresponding to a 37,136% quorum.

The detailed resolutions, voting results, related documents and an AGM recording will be provided in the 2026 Annual General Meeting section of the company’s website. Innate Pharma is a clinical-stage biotechnology company developing next-generation antibody-based immunotherapies for cancer, with collaborations including AstraZeneca and Sanofi.

Key Figures

Shares with voting rights: 34,872,293 shares Total voting rights: 34,921,313 voting rights AGM quorum: 37,136%

3 metrics

Shares with voting rights 34,872,293 shares Shares giving right to voting rights at 2026 AGM

Total voting rights 34,921,313 voting rights Voting rights referenced for 2026 AGM

AGM quorum 37,136% Quorum for the 2026 Annual General Meeting

Key Terms

Annual General Meeting, voting rights, clinical-stage biotechnology company, immunotherapies, +2 more

6 terms

Annual General Meeting financial

"announced the voting results of its shareholders at the Annual General Meeting"

voting rights financial

"shares giving right to 34,921,313 voting rights, representing a quorum"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

clinical-stage biotechnology company financial

"Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies"

immunotherapies medical

"biotechnology company developing immunotherapies for cancer patients"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

Universal Registration Document regulatory

"Risk Factors section of the Universal Registration Document filed with the French Financial Markets Authority"

A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.

non-small cell lung cancer medical

"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Innate Pharma (IPHA) announce in its May 2026 Form 6-K?

Innate Pharma announced the voting results of its 2026 Annual General Meeting. All resolutions were voted, and detailed results, documents, and a recording will be made available in the Annual General Meeting 2026 section of the company’s website.

What was the shareholder quorum at Innate Pharma’s 2026 AGM?

The 2026 AGM recorded a quorum of 37,136% based on voting rights. A total of 94 votes were cast, out of 34,872,293 shares representing 34,921,313 voting rights, according to the company’s disclosure in the AGM outcome press release.

Where can investors find detailed voting results for Innate Pharma’s 2026 AGM?

Investors can find detailed resolutions, vote counts, and related documents in the Annual General Meeting 2026 section of Innate Pharma’s website. The company also plans to provide an AGM recording there, offering further transparency into the meeting discussions and outcomes.

What kind of company is Innate Pharma (Euronext: IPH; Nasdaq: IPHA)?

Innate Pharma is a global clinical-stage biotechnology company focused on immunotherapies for cancer. It develops next-generation antibody therapeutics and advances assets like IPH4502, lacutamab, and monalizumab, working in collaboration with partners such as AstraZeneca, Sanofi, and leading research institutions.

Which key oncology programs does Innate Pharma highlight in this disclosure?

Innate Pharma highlights IPH4502, a differentiated Nectin-4 antibody-drug conjugate, lacutamab, an anti-KIR3DL2 antibody for T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AstraZeneca in non-small cell lung cancer, as core components of its clinical pipeline.

On which exchanges are Innate Pharma shares listed and under which tickers?

Innate Pharma’s shares are listed on Euronext Paris under the ticker IPH and on Nasdaq in the United States under the ticker IPHA. The company’s shares carry ISIN code FR0010331421 and have a legal entity identifier assigned for regulatory purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Friday May 22, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated May 22, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: May 22, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson

Title:    Chief Executive officer

EXHIBIT 99.1

Outcome of Innate Pharma’s 2026 Annual General Meeting

Marseille, France, May 22, 2026, 7:00 AM CEST

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 21, 2026, in Marseille. All resolutions were voted.

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026 section of the Company’s website.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code FR0010331421

Ticker code Euronext: IPH Nasdaq: IPHA

LEI    9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors & Media Relations

Innate Pharma

Stéphanie Cornen

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 10.8 KB